Comparative Pharmacology
Head-to-head clinical analysis: AMINOHIPPURATE SODIUM versus R GENE 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOHIPPURATE SODIUM versus R GENE 10.
AMINOHIPPURATE SODIUM vs R-GENE 10
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminohippurate sodium is a diagnostic agent used to measure effective renal plasma flow (ERPF) by competitive inhibition of tubular secretion of para-aminohippurate (PAH) via organic anion transporters (OAT1 and OAT3) in the proximal tubule, allowing clearance calculations.
Arginine is a semi-essential amino acid that serves as a substrate for nitric oxide (NO) synthesis via nitric oxide synthase (NOS), leading to vasodilation. It also stimulates growth hormone release and is involved in the urea cycle for ammonia detoxification.
For measurement of effective renal plasma flow (ERPF): 0.2 mL/kg of a 20% solution (40 mg/kg) administered intravenously over 1-2 minutes, followed by continuous intravenous infusion of 0.5 mL/min of a solution containing 4.5 g aminohippurate sodium in 500 mL normal saline (9 mg/mL) to maintain stable plasma levels.
10 mg intravenously over 1-2 minutes, once daily for 5 days, repeat course after 2-3 weeks if needed.
None Documented
None Documented
Terminal elimination half-life is approximately 0.5–1.0 hour; used to measure effective renal plasma flow (ERPF).
Terminal elimination half-life is 2-4 hours (mean 3 hours) in adults with normal renal function; prolonged to 8-18 hours in renal impairment.
Primarily renal: ~90% excreted unchanged by tubular secretion; <5% fecal.
Primarily renal (approximately 80-90% unchanged). Biliary/fecal elimination accounts for <5%.
Category C
Category C
Diagnostic Agent
Diagnostic Agent